Compounds > nevirapine

nevirapine and rilpivirine

nevirapine has been researched along with rilpivirine in 49 studies

Research

Studies (49)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (8.16)29.6817
2010's34 (69.39)24.3611
2020's11 (22.45)2.80

Authors

AuthorsStudies
Andries, K; Arnold, E; Bohets, H; Clark, AD; Daeyaert, F; Das, K; de Béthune, MP; De Clerck, F; de Jonge, M; De Knaep, F; Frenkel, YV; Guillemont, J; Heeres, J; Hughes, SH; Janssen, PA; Koymans, L; Kukla, M; Lampo, A; Lewi, PJ; Ludovici, D; Medaer, B; Pasquier, E; Pauwels, R; Stoffels, P; Vinkers, M; Williams, P1
Andries, K; Arnold, E; Bettens, E; Daeyaert, FF; Das, K; de Béthune, MP; de Jonge, MR; Gaurrand, S; Guillemont, J; Heeres, J; Hertogs, K; Janssen, PA; Koymans, LM; Lewi, PJ; Palandjian, P; Pasquier, E; Pauwels, R; Timmerman, P; Vernier, D; Vinkers, MH; Wigerinck, P1
Bettens, E; Demestre, C; Guillemont, J; Heeres, J; Hertogs, K; Lewi, P; Masungi, C; Mordant, C; Pasquier, E; Peeters, A; Queguiner, L; Schmitt, B; Smeulders, L1
Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E1
Azijn, H; Boven, K; de Béthune, MP; Jochmans, D; Kraus, G; Picchio, G; Rimsky, LT; Tirry, I; Van Craenenbroeck, E; Vingerhoets, J1
Anderson, KS; Bollini, M; Domaoal, RA; Gallardo-Macias, R; Jorgensen, WL; Spasov, KA; Thakur, VV1
Anderson, KS; Bollini, M; Gallardo-Macias, R; Jorgensen, WL; Spasov, KA; Tirado-Rives, J1
Chen, FE; Daelemans, D; De Clercq, E; Liu, Y; Ma, XD; Pannecouque, C; Yang, S1
Anderson, KS; Arnold, E; Bauman, JD; Bollini, M; Cisneros, JA; Das, K; Frey, KM; Jorgensen, WL; Spasov, KA1
Anderson, KS; Bollini, M; Cisneros, JA; Jorgensen, WL; Spasov, KA1
Balzarini, J; Chen, W; De Clercq, E; Liu, H; Liu, X; Pannecouque, C; Rai, D; Zhan, P; Zhou, Z1
Anderson, KS; Bollini, M; Frey, KM; Gallardo-Macias, R; Jorgensen, WL; Lee, WG; Spasov, KA1
Elgaher, WA; Hartmann, RW; Haupenthal, J; Mély, Y; Pires, M; Real, E; Saladini, F; Sharma, KK1
Jorgensen, WL1
Devale, TL; Miniyar, P; Murumkar, P; Parikh, J; Sharma, P; Shrivastava, B1
Chen, CH; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Lee, KH; Liu, J; Liu, X; Liu, Z; Pannecouque, C; Tian, Y; Zhan, P; Zhang, H1
Byrareddy, SN; Kongsted, J; Kramer, VG; Kurup, S; Liu, X; Namasivayam, V; Vanangamudi, M; Zhan, P1
Daelemans, D; De Clercq, E; Kang, D; Liu, X; Pannecouque, C; Tian, Y; Wang, Z; Yu, Z; Zhan, P; Zhang, J1
Anderson, KS; Frey, KM; Gannam, ZTK; Jorgensen, WL; Kudalkar, SN; Lee, WG; Sasaki, T; Spasov, KA1
Arnold, E; De Clercq, E; Fang, Z; Feng, D; Kang, D; Liu, X; Pannecouque, C; Pilch, A; Ruiz, FX; Sun, Y; Wang, Z; Wei, F; Zhan, P; Zhao, T1
Anderson, KS; Bertoletti, N; Carter, ZJ; Cisneros, JA; Cutrona, KJ; Ippolito, JA; Jin, S; Jorgensen, WL; Niu, H; Spasov, KA; Valhondo, M1
Arnold, E; De Clercq, E; Feng, D; Gao, S; Jing, L; Kang, D; Liu, X; Pannecouque, C; Ruiz, FX; Sun, L; Sun, Y; Wang, Z; Zhan, P; Zhang, T1
Chen, FE; De Clercq, E; Ding, L; Pannecouque, C; Zhuang, C3
Cherukupalli, S; De Clercq, E; Jia, R; Jiang, X; Kang, D; Liu, X; Pannecouque, C; Wang, W; Wang, Z; Xie, M; Zhan, P1
Chen, FE; De Clercq, E; Huang, WJ; Jin, X; Pannecouque, C; Wang, S; Zhang, YX; Zhao, LM1
Chen, FE; Clercq, E; Hao, QQ; Ling, X; Pannecouque, C1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Debyser, Z; Desimmie, BA; Schrijvers, R1
Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Klinbuayaem, V; Munsakul, W; Petoumenos, K; Prasithsirikul, W; Ruxrungtham, K; Sirivichayakul, S; Sungkanuparph, S1
Giaquinto, C; Penazzato, M1
Davis, PH; Minkara, MS; Radhakrishnan, ML1
Balamane, M; Fessel, WJ; Katzenstein, DA; Melikian, GL; Shafer, RW; Varghese, V1
El-Nahal, WG; Monroe, JI; Shirts, MR1
Colby-Germinario, SP; Han, Y; Huang, W; Oliveira, M; Petropoulos, CJ; Quan, Y; Wainberg, MA; Xu, HT1
Back, D; Kaye, S; Khoo, S; Mackie, NE; Mora-Peris, B; Vera, JH; Waldman, AD; Watson, V; Weston, R; Winston, A1
Allavena, C; André-Garnier, E; Billaud, E; Bonnet, B; Bouchez, S; Bouquié, R; Boutoille, D; Dailly, E; Pineau, S; Raffi, F; Raveleau, A; Reliquet, V1
Crawford, KW1
Blonk, M; Burger, D; Rijnders, BJ; Rokx, C; Verbon, A1
Aboulker, JP; Charreau, I; de Castro, N; Delaugerre, C; Gallien, S; Mahjoub, N; Molina, JM; Nere, ML; Simon, F1
Camacho, RJ; Gomes, P; Rhee, SY; Theys, K; Vandamme, AM1
Hannongbua, S; Ishii, K; Kato, K; Thammaporn, R; Uchiyama, S; Yagi-Utsumi, M1
Avihingsanon, A; Mekprasan, S; Ohata, PJ; Putcharoen, O; Ruxrungtham, K; Sirivichayakul, S; Teeranaipong, P1
Diphoko, T; Essex, M; Gaseitsiwe, S; Kasvosve, I; Makhema, J; Marlink, R; Moyo, S; Musonda, R; Novitsky, V; Okatch, H; Wainberg, M1
Abraham, OC; Demosthenes, JP; Ghale, BC; Kannangai, R; Ramalingam, VV; Rupali, P; Varghese, GM1
Andreoni, M; Antinori, A; Bagnarelli, P; Borghi, V; Bruzzone, B; Callegaro, AP; De Gennaro, M; Gianotti, N; Maffongelli, G; Maggiolo, F; Saladini, F; Sterrantino, G; Vergori, A; Zaccarelli, M; Zazzi, M1
Barnard, JP; Huber, KD; Sluis-Cremer, N1
Choengpanya, K; Choowongkomon, K; Kiriwan, D; Lamtha, T; Rattanabunyong, S; Rattanasrisomporn, J; Shaikh, AR; Suwattanasophon, C; Wolschann, P1

Reviews

3 review(s) available for nevirapine and rilpivirine

ArticleYear
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
    Journal of medicinal chemistry, 2005, Mar-24, Volume: 48, Issue:6

    Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Genome, Viral; HIV; HIV Infections; Humans; Interdisciplinary Communication; Models, Molecular; Molecular Structure; Mutation; Nitriles; Pyrimidines; Rilpivirine

2005
Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2019, 02-01, Volume: 27, Issue:3

    Topics: Acetamides; Anti-HIV Agents; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Prodrugs; Pyridones; Reverse Transcriptase Inhibitors; Triazoles

2019
Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
    Drugs, 2011, Nov-12, Volume: 71, Issue:16

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; HIV Infections; Humans; Infant; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine

2011

Trials

3 trial(s) available for nevirapine and rilpivirine

ArticleYear
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Antiviral therapy, 2011, Volume: 16, Issue:7

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Stavudine

2011
The efficacy, pharmacokinetics, and safety of a nevirapine to rilpivirine switch in virologically suppressed HIV-1-infected patients.
    Journal of acquired immune deficiency syndromes (1999), 2015, Jan-01, Volume: 68, Issue:1

    Topics: HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Prospective Studies; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Viral Load

2015
Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:2

    Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Retreatment; Reverse Transcriptase Inhibitors; Rilpivirine; Young Adult

2015

Other Studies

43 other study(ies) available for nevirapine and rilpivirine

ArticleYear
Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1.
    Journal of medicinal chemistry, 2005, Mar-24, Volume: 48, Issue:6

    Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Stereoisomerism; Structure-Activity Relationship

2005
Synthesis of novel diarylpyrimidine analogues of TMC278 and their antiviral activity against HIV-1 wild-type and mutant strains.
    European journal of medicinal chemistry, 2007, Volume: 42, Issue:5

    Topics: Animals; Chromatography, High Pressure Liquid; Dogs; Female; HIV-1; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Nitriles; Pyrimidines; Rats; Rats, Wistar; Reverse Transcriptase Inhibitors; Rilpivirine; Spectrophotometry, Ultraviolet

2007
Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
    Bioorganic & medicinal chemistry, 2009, Jan-15, Volume: 17, Issue:2

    Topics: Anti-Infective Agents; Antiviral Agents; Artificial Intelligence; Computer Simulation; Drug Evaluation, Preclinical; Molecular Structure; Quantitative Structure-Activity Relationship

2009
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cells, Cultured; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Molecular Structure; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine

2010
Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
    Journal of medicinal chemistry, 2011, Dec-22, Volume: 54, Issue:24

    Topics: Anti-HIV Agents; Catechols; Computer Simulation; Ethers; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Protein Binding; Quantitative Structure-Activity Relationship; Reverse Transcriptase Inhibitors; Stereoisomerism; T-Lymphocytes

2011
Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.
    Bioorganic & medicinal chemistry letters, 2013, Feb-15, Volume: 23, Issue:4

    Topics: Anti-HIV Agents; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2013
Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2013, Volume: 65

    Topics: Anti-HIV Agents; Benzophenones; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2013
Extension into the entrance channel of HIV-1 reverse transcriptase--crystallography and enhanced solubility.
    Bioorganic & medicinal chemistry letters, 2013, Sep-15, Volume: 23, Issue:18

    Topics: Anti-HIV Agents; Crystallography, X-Ray; Dose-Response Relationship, Drug; Enzyme Inhibitors; HIV Reverse Transcriptase; HIV-1; Models, Molecular; Molecular Structure; Pyrimidines; Solubility; Structure-Activity Relationship

2013
Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
    Bioorganic & medicinal chemistry letters, 2013, Sep-15, Volume: 23, Issue:18

    Topics: Anti-HIV Agents; Cell Line, Transformed; Cell Proliferation; Dose-Response Relationship, Drug; HIV-1; Humans; Hydrazines; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Solubility; Structure-Activity Relationship

2013
Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
    Bioorganic & medicinal chemistry, 2014, Mar-15, Volume: 22, Issue:6

    Topics: Anti-HIV Agents; Crystallization; Dose-Response Relationship, Drug; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2014
Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.
    ACS medicinal chemistry letters, 2014, Nov-13, Volume: 5, Issue:11

    Topics:

2014
Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
    Journal of medicinal chemistry, 2016, Aug-11, Volume: 59, Issue:15

    Topics: Anti-Bacterial Agents; Anti-HIV Agents; Carboxylic Acids; DNA-Directed RNA Polymerases; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Escherichia coli; HEK293 Cells; HeLa Cells; HIV; Humans; Microbial Sensitivity Tests; Molecular Structure; RNA-Directed DNA Polymerase; Structure-Activity Relationship; Thiophenes

2016
Computer-aided discovery of anti-HIV agents.
    Bioorganic & medicinal chemistry, 2016, 10-15, Volume: 24, Issue:20

    Topics: Anti-HIV Agents; Computer-Aided Design; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; T-Lymphocytes

2016
Dihydropyrimidinone-isatin hybrids as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Bioorganic chemistry, 2017, Volume: 70

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Isatin; Molecular Docking Simulation; Pyrimidinones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2017
Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
    European journal of medicinal chemistry, 2018, May-10, Volume: 151

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Niacinamide; Point Mutation; Structure-Activity Relationship; Triazoles

2018
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
    Journal of medicinal chemistry, 2019, 05-23, Volume: 62, Issue:10

    Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Discovery; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors

2019
Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.
    Bioorganic & medicinal chemistry letters, 2019, 08-15, Volume: 29, Issue:16

    Topics: Anti-HIV Agents; Catechols; Drug Design; HIV Reverse Transcriptase; Molecular Structure; Reverse Transcriptase Inhibitors

2019
Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.
    Journal of medicinal chemistry, 2020, 02-13, Volume: 63, Issue:3

    Topics: Animals; Anti-HIV Agents; Cell Line; Crystallography, X-Ray; Drug Discovery; ERG1 Potassium Channel; Female; Fluorine; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mice; Microsomes, Liver; Molecular Structure; Protein Binding; Pyrimidines; Rats, Wistar; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiophenes

2020
Covalent Inhibition of Wild-Type HIV-1 Reverse Transcriptase Using a Fluorosulfate Warhead.
    ACS medicinal chemistry letters, 2021, Feb-11, Volume: 12, Issue:2

    Topics:

2021
2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies.
    Journal of medicinal chemistry, 2021, 04-08, Volume: 64, Issue:7

    Topics: Animals; Anti-HIV Agents; Crystallography, X-Ray; Drug Design; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Mice; Microbial Sensitivity Tests; Molecular Structure; Mutation; Protein Binding; Pyrimidines; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2021
Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
    Journal of medicinal chemistry, 2021, 04-22, Volume: 64, Issue:8

    Topics: Alkylation; Animals; Binding Sites; Biphenyl Compounds; Cell Line; Cell Survival; Drug Design; Drug Stability; Female; Half-Life; HIV Reverse Transcriptase; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Microsomes, Liver; Molecular Docking Simulation; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2021
Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
    Journal of medicinal chemistry, 2021, 07-22, Volume: 64, Issue:14

    Topics: Animals; Anti-HIV Agents; Dose-Response Relationship, Drug; Female; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Models, Molecular; Molecular Structure; Pyrimidines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2021
Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
    Journal of medicinal chemistry, 2022, 02-10, Volume: 65, Issue:3

    Topics: Animals; Anti-HIV Agents; Binding Sites; Cell Survival; Cytochrome P-450 Enzyme System; Drug Design; Drug Resistance, Viral; Drug Stability; Female; Half-Life; HIV Reverse Transcriptase; HIV-1; Humans; Mice; Molecular Docking Simulation; Mutation; Pyridines; Pyrimidines; Solubility; Structure-Activity Relationship

2022
Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
    Journal of medicinal chemistry, 2022, 03-10, Volume: 65, Issue:5

    Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Heterocyclic Compounds, 1-Ring; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Reverse Transcriptase Inhibitors

2022
Structure-Based Discovery of Novel NH
    Journal of medicinal chemistry, 2022, 06-23, Volume: 65, Issue:12

    Topics: Anti-HIV Agents; Biphenyl Compounds; Drug Design; Heterocyclic Compounds, 1-Ring; HIV Reverse Transcriptase; HIV-1; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2022
Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
    European journal of medicinal chemistry, 2022, Aug-05, Volume: 238

    Topics: Animals; Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Mice; Molecular Docking Simulation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2022
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Rilpivirine: a step forward in tailored HIV treatment.
    Lancet (London, England), 2011, Jul-16, Volume: 378, Issue:9787

    Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Design; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Multicenter Studies as Topic; Mutation; Nevirapine; Nitriles; Organophosphonates; Pyrimidines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Viral Load

2011
Multiple drugs and multiple targets: an analysis of the electrostatic determinants of binding between non-nucleoside HIV-1 reverse transcriptase inhibitors and variants of HIV-1 RT.
    Proteins, 2012, Volume: 80, Issue:2

    Topics: Alkynes; Benzoxazines; Binding Sites; Cyclopropanes; HIV Reverse Transcriptase; Mutation; Nevirapine; Nitriles; Protein Conformation; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Static Electricity

2012
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cloning, Molecular; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine

2012
Investigating the mutation resistance of nonnucleoside inhibitors of HIV-RT using multiple microsecond atomistic simulations.
    Proteins, 2014, Volume: 82, Issue:1

    Topics: HIV Reverse Transcriptase; Models, Molecular; Molecular Dynamics Simulation; Mutation; Nevirapine; Nitriles; Principal Component Analysis; Protein Conformation; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine

2014
Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:11

    Topics: Alkynes; Amino Acid Substitution; Benzoxazines; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Virus Replication

2013
Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:6

    Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cerebrospinal Fluid; Drug Substitution; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Nitriles; Pyrimidines; Rilpivirine; Semen; Viral Load

2014
Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
    The Journal of antimicrobial chemotherapy, 2014, Volume: 69, Issue:10

    Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Nitriles; Organophosphonates; Prospective Studies; Pyrimidines; Rilpivirine; Tenofovir; Treatment Outcome; Viral Load

2014
Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes.
    AIDS (London, England), 2014, Sep-24, Volume: 28, Issue:15

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation, Missense; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Treatment Outcome; Viral Load

2014
Predicted residual activity of rilpivirine in HIV-1 infected patients failing therapy including NNRTIs efavirenz or nevirapine.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2015, Volume: 21, Issue:6

    Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Mutation, Missense; Nevirapine; Rilpivirine; Treatment Failure

2015
Mass Spectrometric Characterization of HIV-1 Reverse Transcriptase Interactions with Non-nucleoside Reverse Transcriptase Inhibitors.
    Biological & pharmaceutical bulletin, 2016, Volume: 39, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Reverse Transcriptase; Mass Spectrometry; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine

2016
Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Thailand; Viral Load; Young Adult

2016
Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
    AIDS research and human retroviruses, 2018, Volume: 34, Issue:8

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Botswana; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Genotyping Techniques; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Mutation; Nevirapine; Nitriles; pol Gene Products, Human Immunodeficiency Virus; Prevalence; Pyridazines; Pyrimidines; Rilpivirine; Treatment Failure; Young Adult

2018
Frequency of cross-resistance to rilpivirine and etravirine among HIV-1 subtype C infected individuals failing nevirapine/efavirenz based ART regimen.
    Infectious diseases (London, England), 2019, Volume: 51, Issue:1

    Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Sweden

2019
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    International journal of antimicrobial agents, 2019, Volume: 53, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome; Triazoles

2019
Nonnucleoside Reverse Transcriptase Inhibitor Hypersusceptibility and Resistance by Mutation of Residue 181 in HIV-1 Reverse Transcriptase.
    Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:8

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Fluorescence Polarization; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Rilpivirine

2019
Biochemical and structural comparisons of non-nucleoside reverse transcriptase inhibitors against feline and human immunodeficiency viruses.
    Journal of veterinary science, 2023, Volume: 24, Issue:5

    Topics: Animals; Anti-HIV Agents; Cat Diseases; Cats; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Nevirapine; Reverse Transcriptase Inhibitors; Rilpivirine

2023